Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug-Eluting Stent Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

Cypher beats Taxus in new meta-analysis: Johnson & Johnson's Cypher sirolimus-eluting coronary stent is associated with lower rates of myocardial infarction than either Boston Scientific's Taxus drug-eluting stent or bare-metal stents, according to a meta-analysis of 38 trials with 18,023 patients published in the Sept. 15 issue of The Lancet. The meta-analysis, led by Christoph Stettler, University of Bern (Switzerland), is a network of head-to-head comparisons combining direct within-trial comparisons between stents and indirect evidence from other trials, matched to maintain randomization. In the analysis, Cypher's hazard ratio for myocardial infarction is 0.81 compared to bare-metal stents and 0.83 compared to Taxus. (A hazard ratio <1.0 indicates less risk.) There was no difference in mortality or overall stent thrombosis between the stents, but the risk of late stent thrombosis (after 30 days) was higher with Taxus (hazard ratio 2.11 compared to bare-metal stents and 1.85 compared to Cypher.) Also, the lower rate of target lesion revascularization seen using drug-eluting stents over bare-metal stents was more pronounced with Cypher than with Taxus, according to Stettler et al

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts